INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE

S. Sopper, S. Mustjoki, G. Gastl, Z. Trajanoski, F. Giles, A. Hochhaus, J. Janssen, S. Geisler, D. Fuchs, D. Wolf

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Original languageEnglish
JournalHaematologica
Volume102
Pages (from-to)232-233
Number of pages2
ISSN0390-6078
Publication statusPublished - 26 Jun 2017
Event22nd Congress of the European-Hematology-Association - Madrid, Spain
Duration: 22 Jun 201725 Jun 2017

Cite this

Sopper, S. ; Mustjoki, S. ; Gastl, G. ; Trajanoski, Z. ; Giles, F. ; Hochhaus, A. ; Janssen, J. ; Geisler, S. ; Fuchs, D. ; Wolf, D. / INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE. In: Haematologica. 2017 ; Vol. 102. pp. 232-233.
@article{7c54f0f3aaf94339b7db22802c8c7c27,
title = "INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE",
author = "S. Sopper and S. Mustjoki and G. Gastl and Z. Trajanoski and F. Giles and A. Hochhaus and J. Janssen and S. Geisler and D. Fuchs and D. Wolf",
year = "2017",
month = "6",
day = "26",
language = "English",
volume = "102",
pages = "232--233",
journal = "Haematologica",
issn = "0390-6078",
publisher = "FERRATA STORTI FOUNDATION",

}

INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE. / Sopper, S.; Mustjoki, S.; Gastl, G.; Trajanoski, Z.; Giles, F.; Hochhaus, A.; Janssen, J.; Geisler, S.; Fuchs, D.; Wolf, D.

In: Haematologica, Vol. 102, 26.06.2017, p. 232-233.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

TY - JOUR

T1 - INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE

AU - Sopper, S.

AU - Mustjoki, S.

AU - Gastl, G.

AU - Trajanoski, Z.

AU - Giles, F.

AU - Hochhaus, A.

AU - Janssen, J.

AU - Geisler, S.

AU - Fuchs, D.

AU - Wolf, D.

PY - 2017/6/26

Y1 - 2017/6/26

M3 - Meeting Abstract

VL - 102

SP - 232

EP - 233

JO - Haematologica

JF - Haematologica

SN - 0390-6078

ER -